Pediatrics at CU School of Medicine is among the best in the nation! World-class pediatric residency program and research facilities. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.

Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK.

Blood Cancer J. 2013 Jan 25;3:e101

Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, Deryckere D, Graham DK.

J Hematol Oncol. 2013 Jan 23;6:10

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, Deryckere D,Heasley LE, Graham DK.

Oncogene. 2012 Aug 13

Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.

Migdall-Wilson J, Bates C, Schlegel J, Brandão L, Linger RM, DeRyckere D, Graham DK.

PLoS One. 2012;7(2):e31635

TAM receptors in leukemia: expression, signaling, and therapeutic implications.

Brandão L, Migdall-Wilson J, Eisenman K, Graham DK.

Crit Rev Oncog. 2011;16(1-2):47-63.

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.